The use of antisense oligodeoxynucleotides (aODNs) for the therapy of cancer

A. Alama, F. Barbieri, F. Bottini, A. Nicolin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although specific cancer targets are difficult to identify, the recent development of antisense oligodeoxynucleotides (aODNs) as inhibitors of gene expression has been shown to provide a new and useful tool in antiblastic management. aODNs are able to specifically interact with gene or mRNA sequences and inhibit the expression of relevant molecules for cancer pathogenesis and progression. Since α-DNA polymerase (pol-α) plays an essential role in cell proliferation, aODNs to pol-α have been synthesized in order to block mRNA translation and affect the growth of MDA-MB 231, human breast cancer cell line and SW626 ovarian cancer cells. A rapid colorimetric test (MTT assay) which measures cell growth and survival has been employed to evaluate the effects induced by ODN treatment. The present experimental results demonstrate that the aODNs to pol-α are able to significantly affect cell proliferation. This study provides an encouraging basis for the exploitation of ODNs as therapeutic agents in vitro and in future clinical application.

Original languageEnglish
Pages (from-to)575-579
Number of pages5
JournalDrugs under Experimental and Clinical Research
Volume17
Issue number12
Publication statusPublished - 1991

Fingerprint

Oligodeoxyribonucleotides
Neoplasms
Cell Proliferation
Protein Biosynthesis
DNA-Directed DNA Polymerase
Therapeutics
Growth
Ovarian Neoplasms
Cell Survival
Breast Neoplasms
Gene Expression
Cell Line
Messenger RNA
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

The use of antisense oligodeoxynucleotides (aODNs) for the therapy of cancer. / Alama, A.; Barbieri, F.; Bottini, F.; Nicolin, A.

In: Drugs under Experimental and Clinical Research, Vol. 17, No. 12, 1991, p. 575-579.

Research output: Contribution to journalArticle

Alama, A. ; Barbieri, F. ; Bottini, F. ; Nicolin, A. / The use of antisense oligodeoxynucleotides (aODNs) for the therapy of cancer. In: Drugs under Experimental and Clinical Research. 1991 ; Vol. 17, No. 12. pp. 575-579.
@article{7ab1976704274e3bac028d1881ec3336,
title = "The use of antisense oligodeoxynucleotides (aODNs) for the therapy of cancer",
abstract = "Although specific cancer targets are difficult to identify, the recent development of antisense oligodeoxynucleotides (aODNs) as inhibitors of gene expression has been shown to provide a new and useful tool in antiblastic management. aODNs are able to specifically interact with gene or mRNA sequences and inhibit the expression of relevant molecules for cancer pathogenesis and progression. Since α-DNA polymerase (pol-α) plays an essential role in cell proliferation, aODNs to pol-α have been synthesized in order to block mRNA translation and affect the growth of MDA-MB 231, human breast cancer cell line and SW626 ovarian cancer cells. A rapid colorimetric test (MTT assay) which measures cell growth and survival has been employed to evaluate the effects induced by ODN treatment. The present experimental results demonstrate that the aODNs to pol-α are able to significantly affect cell proliferation. This study provides an encouraging basis for the exploitation of ODNs as therapeutic agents in vitro and in future clinical application.",
author = "A. Alama and F. Barbieri and F. Bottini and A. Nicolin",
year = "1991",
language = "English",
volume = "17",
pages = "575--579",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "12",

}

TY - JOUR

T1 - The use of antisense oligodeoxynucleotides (aODNs) for the therapy of cancer

AU - Alama, A.

AU - Barbieri, F.

AU - Bottini, F.

AU - Nicolin, A.

PY - 1991

Y1 - 1991

N2 - Although specific cancer targets are difficult to identify, the recent development of antisense oligodeoxynucleotides (aODNs) as inhibitors of gene expression has been shown to provide a new and useful tool in antiblastic management. aODNs are able to specifically interact with gene or mRNA sequences and inhibit the expression of relevant molecules for cancer pathogenesis and progression. Since α-DNA polymerase (pol-α) plays an essential role in cell proliferation, aODNs to pol-α have been synthesized in order to block mRNA translation and affect the growth of MDA-MB 231, human breast cancer cell line and SW626 ovarian cancer cells. A rapid colorimetric test (MTT assay) which measures cell growth and survival has been employed to evaluate the effects induced by ODN treatment. The present experimental results demonstrate that the aODNs to pol-α are able to significantly affect cell proliferation. This study provides an encouraging basis for the exploitation of ODNs as therapeutic agents in vitro and in future clinical application.

AB - Although specific cancer targets are difficult to identify, the recent development of antisense oligodeoxynucleotides (aODNs) as inhibitors of gene expression has been shown to provide a new and useful tool in antiblastic management. aODNs are able to specifically interact with gene or mRNA sequences and inhibit the expression of relevant molecules for cancer pathogenesis and progression. Since α-DNA polymerase (pol-α) plays an essential role in cell proliferation, aODNs to pol-α have been synthesized in order to block mRNA translation and affect the growth of MDA-MB 231, human breast cancer cell line and SW626 ovarian cancer cells. A rapid colorimetric test (MTT assay) which measures cell growth and survival has been employed to evaluate the effects induced by ODN treatment. The present experimental results demonstrate that the aODNs to pol-α are able to significantly affect cell proliferation. This study provides an encouraging basis for the exploitation of ODNs as therapeutic agents in vitro and in future clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0026336217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026336217&partnerID=8YFLogxK

M3 - Article

C2 - 1841051

AN - SCOPUS:0026336217

VL - 17

SP - 575

EP - 579

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 12

ER -